Tarextumab (OMP-59R5), a monoclonal antibody (mAb) against Notch2 and Notch3, has shown promising antitumor activity in several in vitro and in vivo models of SCLC, breast, ovarian, and pancreatic cancer that correlated with downregulation of Notch target genes [205]. This evidence concerns the gene NOTCH2 and small cell lung carcinoma.